BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Veloxis Pharmaceuticals A/S (VELO)' Phase 3 Trial of LCP-Tacro™ in Stable Kidney Transplant Patients, the 3001 Study, Published Online in the American Journal of Transplantation


1/3/2013 9:27:34 AM

HORSHOLM, Denmark, Jan. 3, 2013 /PRNewswire/ -- Veloxis Pharmaceuticals A/S today is announcing that the LCP-Tacro Phase III clinical trial in stable kidney transplant patients, the 3001 study, has been published online in the American Journal of Transplantation. The article reports on the randomized, controlled, multicenter Phase III trial, which demonstrated that LCP-Tacro dosed once-daily was not inferior to the current leading transplant drug, Prograf®, dosed twice-daily. Non-inferiority was determined by a composite endpoint, measured over a year of follow up that included death, graft failure, biopsy-proven acute rejection or loss to follow-up.

Results of this trial demonstrated that patients can be successfully converted from twice-daily Prograf to once-daily LCP-Tacro, which may increase patient compliance. Non-adherence to drug regimens is a contributor to graft failure (Prog. Transplant, 19:277-284, 2009). The results also demonstrated that, over the 12 month study, the daily dose of LCP-Tacro could be lowered significantly compared to the baseline Prograf dose, while the target blood levels remained stable and within target range. This reflected the enhanced bioavailability provided by Veloxis' proprietary MeltDose® formulation. The technology optimizes the formulation and delivery characteristics of the LCP-Tacro product to permit once daily dosing.

"Our study showed thatLCP-Tacro may be a safe and effective once-daily formulation for preventing rejection, and an alternative to currently available twice-daily tacrolimus," said Suphamai Bunnapradist, M.D., Professor of Medicine at David Geffen School of Medicine at UCLA. "LCP-Tacro required lower doses to achieve target levels in the blood, had similar rates of adverse events, and demonstrated non-inferiority to the twice daily regimen of tacrolimus in stable patients."

William Polvino, M.D. and chief executive officer of Veloxis added, "We have reached another milestone by the publication of the 3001 study in the American Journal of Transplantation. We are now looking forward to completing the 3002 study in de novo kidney transplant patients and releasing top-line data in mid-2013."

For Investor and media contact:

John Weinberg, M.D.
EVP & Chief Commercial Officer
Phone: +1 732 321 3208
Email: jdw@veloxis.com

About LCPTacro and tacrolimus

Tacrolimus is a leading immunosuppression drug used for the prevention of transplant allograft rejection after organ transplantation. LCPTacro is an investigational drug that it is being developed as a oncedaily tablet version of tacrolimus, with improved bioavailability, consistent pharmacokinetic performance and reduced peaktotrough variability when compared to currently approved tacrolimus products. Transplant patients need to maintain a minimum blood level of tacrolimus for the prevention of transplant allograft rejection, but excessive levels may increase the risk of serious side effects such as nephrotoxicity, tremor, diabetes, high blood pressure, and opportunistic infections. Therefore, tacrolimus levels need to be managed carefully, and transplant patients are typically obliged to make frequent visits to the hospital for monitoring and dose adjustments after receiving a new organ.

About Veloxis Pharmaceuticals

Based in Horsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. The company's lead product candidate is LCPTacro for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at lowscale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit www.veloxis.com.

SOURCE Veloxis Pharmaceuticals A/S


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->